What is rituximab MOA?
The direct effects of rituximab include complement-mediated cytotoxicity and antibody-dependent cell-mediated cytotoxicity, and the indirect effects include structural changes, apoptosis, and sensitization of cancer cells to chemotherapy.
Who discovered Rituxan?
This chimeric technology was the basis for rituximab production, and in 1997 the FDA approved rituximab, brand name Rituxan, for use to treat follicular lymphoma (FL) (7). Rituximab was created by Ronald Levy for the express purpose of targeting malignant B cells.
Is Rituximab Monoclonal?
Rituximab is a chimeric mouse/human monoclonal antibody (mAb) therapy with binding specificity to CD20.
What is rituximab monoclonal antibody?
Rituximab is a chimeric monoclonal antibody against the protein CD20, which is primarily found on the surface of immune system B cells. When it binds to this protein it triggers cell death.
What is rituximab target?
Rituximab, a chimeric monoclonal antibody targeted against the pan-B-cell marker CD20, was the first monoclonal antibody to be approved for therapeutic use.
What does RITUXAN do to B-cells?
Rituxan depletes B-cells, which can cause swelling and joint damage in people with autoimmune disorders, such as rheumatoid arthritis. It is also thought to work by depleting B-cells in patients with the autoimmune disorders granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA).
What is RITUXAN made from?
Rituximab is a man-made antibody that was developed using cloning and recombinant DNA technology from human and murine (mice or rat) genes. Rituximab is thought to attach to the CD20 receptor and cause the tumor cells to disintegrate (lyse).
What is the difference between Rituxan and rituximab?
Rituxan is the trade name for rituximab. In some cases, health care professionals may use the trade name rituxan when referring to the generic drug name rituximab. Drug type: Rituximab is a monoclonal antibody. (For more detail, see “How this drug works” section below).
What does rituximab do to CD20?
Rituximab targets CD20, a transmembrane protein present on virtually all B cells from the stage at which they become committed to B-cell development until it is downregulated when they differentiate into antibody-secreting plasma cells (Reff et al., 1994). Thus, CD20 is considered a pan-B-cell antigenic marker.
What do CD20 cells do?
CD20 is a membrane-embedded surface molecule which plays a role in the development and differentiation of B-cells into plasma cells.
What does RITUXAN do to B cells?
When do B cells return after RITUXAN?
Treatment with rituximab results in complete B cell-depletion within 72 h. Recovery of B cell counts usually starts only 6-9 months after the completion of therapy, and normal levels are obtained after 9-12 months (5).
How do you know if Rituxan is working?
Rituximab works by lowering the number of these B-cells, to reduce inflammation, pain, swelling and joint damage. If rituximab works for you, you’ll probably notice an improvement in your symptoms 8-16 weeks after you start treatment.
How long does Rituxan stay in body?
Also, Rituxan may stay in your system 6 to 12 months after your last dose. Because of this, it can be used as a maintenance (long-term) treatment in certain cases. For example, if you have non-Hodgkin’s lymphoma (NHL), you’ll receive a dose of Rituxan with each chemotherapy treatment, for up to 8 doses.
What does Rituxan do to immune system?
It helps the immune system destroy cancer cells. Rituximab injection is a monoclonal antibody. Rituximab injection is used together with other medicines (eg, fludarabine cyclophosphamide) to treat chronic lymphocytic leukemia (CLL).
What is CD20 function?
How does rituximab induce apoptosis?
Rituximab-induced apoptosis in B-CLL cells is related to MAP-kinase phosphorylation and dependent on p38 activity. Binding of anti-CD20 antibodies to CD20 induces phosphorylation of protein tyrosine kinases and calcium mobilization in B-cell lines.
What does CD mean in CD20?
CD20 (cluster of differentiate 20) is a protein that is expressed on the surface of B cells, starting at the pre-B cell stage and on mature B cells in the bone marrow and in the periphery. CD20 is not expressed on hematopoietic stem cells, pro-B cells, or normal plasma cells.